Our Coronavirus Efforts
As a global pharmaceutical leader, we are doing all we can to protect the health of our employees, their families and our communities, while ensuring our medicines continue to reach patients who rely on them. With this in mind, we are taking a number of steps to address COVID-19 and to help minimize its transmission, including developing a plasma-derived therapy to treat high-risk COVID-19 patients. We are also strongly recommending that all employees work from home where possible, in alignment with their site and group requirements.
More information about these efforts can be found below.
|March 25||Takeda Research & Development and COVID-19|
|March 23||Coronavirus and Product Supply|
|March 19||Coronavirus: Adjusting Our Business Approach While Serving Our Patients|
|March 6||Rajeev Venkayya, President, Global Vaccine Business Unit on the latest on the Coronavirus and Takeda|
|March 4||Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19|